FirsthandHealth
gov.uk: Medicines and Healthcare products Regulatory AgencyUnited Kingdom18 November 2026

MHRA launches AdvanceGxP service to support innovative medicine manufacturing

On 18 November 2026, the Medicines and Healthcare products Regulatory Agency announced a new service called AdvanceGxP to support developers of advanced medicine manufacturing technologies. Science, Innovation and Investment Minister Chris McDonald MP disclosed the service during a speech on 17 November at the DIA-MHRA Global Summit in London. Funding for the project comes from the Office for Life Sciences. The service offers earlier guidance to companies using novel manufacturing approaches. These include artificial intelligence, robotics, space-based manufacturing, and bedside production of personalised therapies near hospitals. By addressing regulatory and quality questions early in development, the agency aims to prevent costly redesigns and delays in bringing new treatments to UK patients. To run the service, the agency will recruit a dedicated specialist team. Initial capacity will be limited while the process is tested, with plans to evaluate how it might expand in the future.

What was announced

The Medicines and Healthcare products Regulatory Agency is creating AdvanceGxP, a support service for companies developing new ways to manufacture medicines. Funding from the Office for Life Sciences will allow the regulator to hire a specialist team to run the program.

The service targets emerging production methods. These methods include making personalised medicines at or near clinics, manufacturing in space, and using robotics, automation, and artificial intelligence. Through AdvanceGxP, developers can consult with regulatory experts earlier in their process to resolve Good Practice compliance questions before designs are finalised.

What it means

Creating new medicine technologies often brings regulatory confusion, as standard rules may not fit novel processes. Early advice from the UK regulator helps companies fix compliance issues early rather than facing delays later.

MHRA Chief Executive Lawrence Tallon noted that early support helps solve problems before they cause delays and builds investment confidence in the UK. Kenan Poleo, director at the Office for Life Sciences, stated that keeping regulation up to pace with innovation gives companies confidence to build new technologies locally.

The service also aligns with the MHRA Strategy to 2030, which emphasizes early engagement across the health system to help innovative therapies reach patients.

What the announcement does not tell us

The announcement does not state how much funding the Office for Life Sciences provided for AdvanceGxP. It also does not disclose how many staff will join the new specialist team or when the service will officially open for applications.

It remains unclear which specific technologies or projects the regulator will prioritise during the initial testing period. Furthermore, the document does not explain the exact criteria companies must meet to access the limited places available.

How this was written

This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is gov.uk: Medicines and Healthcare products Regulatory Agency’s own. Always check the original before acting on anything here.

AdvanceGxP will give developers earlier practical support for advanced manufacturing technologies, accelerating patient access to innovative medicines while strengthening UK manufacturing.
Source: gov.uk: Medicines and Healthcare products Regulatory Agency

More from gov.uk: Medicines and Healthcare products Regulatory Agency

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.